Literature analysis of adverse cardiovascular reactions induced by anlotinib
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
维普
万方数据
目的 分析安罗替尼所致心血管不良反应的发生规律和临床特点,为临床安全用药提供参考.方法 检索2018年8月—2022年5月万方、中国知网、维普、PubMed、Web of Science、Embase数据库中安罗替尼致心血管不良反应(ADR)的个案报道,筛选后进行统计分析.结果 共收集20篇个案报道,涉及20例患者,其中男性9例(45.0%),女性11例(55.0%).患者年龄集中在50～69岁,ADR多发生在用药后7～90 d,以高血压最为常见,主动脉夹层、可逆性后部白质脑病综合征、高血压性视网膜病变等ADR未在说明书中提及.结论 临床使用安罗替尼应加强监测,警惕其心血管ADR,尤其注重防治高血压,及时识别并发症,确保临床用药安全.
Objective To analyze the occurrence and clinical characteristics of adverse drug reactions(ADRs)of cardiovascular system induced by anlotinib,and provide reference for clinical safe drug use.Methods Case reports of cardiovascular ADR induced by anlotinib in Wanfang database,China national knowledge infrastructure(CNKI),VIP database,Pubmed,Web of Science and Embase databases from August 2018 to May 2022 were retrieved and statistically analyzed after screening.Results A total of 20 case reports,20 patients were collected,including 9 males(45%)and 11 females(55%)mostly aged from 50 to 69 years old.Cardiovascular ADRs mostly occurred in 7-90 days after administration and hypertension was the most common.Cardiovascular ADRs unmentioned in the label were also involved including aortic dissection,reversible posterior white matter encephalopathy syndrome,hypertensive retinopathy,etc.Conclusion During clinical use of anlotinib,it is suggested to strengthen monitoring,being alert of cardiovascular ADR especially hypertension,timely identify complications,thus to ensure the safety drug use.
维普
万方数据
